SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-008312
Filing Date
2020-05-22
Accepted
2020-05-22 17:13:17
Documents
58
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cpix-20200331.htm   iXBRL 10-Q 1149352
2 EX-31.1 a2020q1-exhibit311.htm EX-31.1 16755
3 EX-31.2 a2020q1-exhibit312.htm EX-31.2 16764
4 EX-32.1 a2020q1-exhibit321.htm EX-32.1 9386
  Complete submission text file 0001628280-20-008312.txt   4600499

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20200331.xsd EX-101.SCH 32606
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20200331_cal.xml EX-101.CAL 73447
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20200331_def.xml EX-101.DEF 124482
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20200331_lab.xml EX-101.LAB 396168
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20200331_pre.xml EX-101.PRE 254006
17 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20200331_htm.xml XML 665661
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 20907011
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences